CatalystFDA/Bio

Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva

FDA approval of Atebrioz for fibrodysplasia ossificans progressiva drives high biotech catalyst score.

What changed

FDA approval of Atebrioz for fibrodysplasia ossificans progressiva drives high biotech catalyst score.

Why it matters

FDA approval of Atebrioz for fibrodysplasia ossificans progressiva drives high biotech catalyst score. — impact context not separately stored; see What changed.

Sources

eodhd